NCT05354609Active, not recruiting
DWI MR-enterography Without or With Bowel Cleansing to Assess Intestinal Inflammatory Activity in the Follow-up of Crohn's Disease
Assessment of Intestinal Inflammatory Activity in the Follow-up of Patients With Crohn's Disease: Diffusion-weighted MR-enterography, Without or With Bowel Cleansing, Compared With Standard MR-enterography
Source: ClinicalTrials.gov · Last updated 19 Nov 2025
Brief summary (registry, in English)
Since 2009, many studies tend to prove the effectiveness of diffusion-weighted MR-enterography in the assessment of inflammatory activity in IBD compared to standard MR-enterography, with the emergence of new radiological scores such as the Clermont score. Diffusion-weighted MRI (DWI) is a faster technique and does not require the injection of gadoline contrast medium, which is a desirable in view of recent data on their long-term adverse effects (intracerebral deposits, nephrogenic systemic fibrosis). The advent of 3T MRI, which provides a better signal, a better spatial resolution or the same examination quality in a shorter time, seems promising for the future of DWI. However, to date, there are still few studies carried out at 3T in this field or even few studies on the possibility of doing away with bowel cleansing, although this is one of the main demands of patients. All patients will undergo a simplified MR-enterography, which includes four sequences, without bowel cleansing or injection. On the same day, the standard MR-enterography will be performed as in clinical practice, after ingestion of the usual oral preparation. Three reading sessions of the examination will be organized at intervals of at least one month by two radiologists specialized in digestive imaging, blinded to the clinical and
- Status (registry)
- Active, not recruiting
- Study type
- Interventional
- Enrollment
- 140 (estimated)
- First submitted
- 26 Apr 2022
- Start date
- 26 Apr 2022
- Primary completion date
- 1 Dec 2024
- Lead sponsor
- Centre Hospitalier Universitaire, Amiens
- Diseases
- Crohn's disease
- NCT number
- NCT05354609
What you commit to
- Study type: Interventional
- Planned participants: 140
- From 26 Apr 2022 to the primary completion date, 1 Dec 2024
- 1 site in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Other illness
- Allergy to gadolinium chelates
Other
- Any contraindication to MRI
- Claustrophobia
- Major obesity that does not allow the patient to enter the machine's tunnel (whose diameter is 70 cm)
- Pregnant woman
- Person under curators or guardianship
Who the study is looking for
- Any patient diagnosed with Crohn's disease with bowel involvement for whom a MR-enterography was ordered as part of their follow-up
- Age ≥ 18
- Subject's ability to understand and express opposition
- Affiliation to French social security system
Age in the registry: 18 years to - · Sex: All · Accepts healthy volunteers
Sites (1)
Sites in registry order. Save your city in your profile to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| CHU Amiens Coordinator of this site? Confirm its status | Amiens | France | Unknown status |
This page is information, not medical advice. Discuss any trial with your doctor.